gsk5733584
mAbexperimentalADC
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Jul 2, 2024 (NCT06431594)
Timeline
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
- Payload
- unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07286331 | Phase 3 | Mar 5, 2026 | European Network for Gynaecological Oncological Trial, GlaxoSmithKline, GOG Foundation, Inc. |
| NCT07286266 | Phase 3 | Mar 3, 2026 | European Network for Gynaecological Oncological Trial, GlaxoSmithKline, GOG Foundation, Inc. |
| NCT06796907 | Phase 1/Phase 2 (Phase 2) | Mar 4, 2025 | GlaxoSmithKline |
| NCT06431594 | Phase 1 | Jul 2, 2024 | GlaxoSmithKline |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 4 | 4 | 3 | 2024 |
| European Network for Gynaecological Oncological Trial | Academic/Hospital | 2 | 0 | 1 | 2026 |
| GOG Foundation, Inc. | Academic/Hospital | 2 | 0 | 1 | 2026 |
3 organizations
Page 1 / 1